207 related articles for article (PubMed ID: 17461857)
21. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
Fox Z; Dragsted UB; Gerstoft J; Phillips AN; Kjaer J; Mathiesen L; Youle M; Katlama C; Hill A; Bruun JN; Clumeck N; Dellamonica P; Lundgren JD;
Antivir Ther; 2006; 11(6):761-70. PubMed ID: 17310820
[TBL] [Abstract][Full Text] [Related]
23. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
24. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study.
Perez-Elias MJ; Garcia-Arota I; Muñoz V; Santos I; Sanz J; Abraira V; Arribas JR; González J; Moreno A; Dronda F; Antela A; Pumares M; Martí-Belda P; Casado JL; Geijos P; Moreno S;
Antivir Ther; 2003 Dec; 8(6):577-84. PubMed ID: 14760891
[TBL] [Abstract][Full Text] [Related]
25. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
Valantin MA; Lanoy E; Bentata M; Kalmykova O; Boutekadjirt A; Allavena C; Rozenbaum W; Peytavin G; Amellal B; Calvez V; Costagliola D; Katlama C;
HIV Med; 2008 Oct; 9(8):625-35. PubMed ID: 18624724
[TBL] [Abstract][Full Text] [Related]
26. Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.
Canestri A; Ghosn J; Wirden M; Marguet F; Ktorza N; Boubezari I; Dominguez S; Bossi P; Caumes E; Calvez V; Katlama C
Antivir Ther; 2006; 11(5):561-6. PubMed ID: 16964823
[TBL] [Abstract][Full Text] [Related]
27. Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients.
Charpentier C; Laureillard D; Sodqi M; Si-Mohamed A; Karmochkine M; Bélec L; Weiss L; Piketty C
J Clin Virol; 2008 Oct; 43(2):212-5. PubMed ID: 18760662
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
29. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
[TBL] [Abstract][Full Text] [Related]
30. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients.
Cahn P; Cassetti I; Wood R; Phanuphak P; Shiveley L; Bethell RC; Sawyer J
AIDS; 2006 Jun; 20(9):1261-8. PubMed ID: 16816554
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
[TBL] [Abstract][Full Text] [Related]
33. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
34. MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study.
Katlama C; Ghosn J; Tubiana R; Wirden M; Valantin MA; Harmenberg J; Mårdh G; Oberg B; Calvez V
AIDS; 2004 Jun; 18(9):1299-304. PubMed ID: 15362662
[TBL] [Abstract][Full Text] [Related]
35. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
36. Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.
Llibre JM; Domingo P; del Pozo MA; Miralles C; Galindo MJ; Viciana I; Moreno S; Schapiro JM; Clotet B
J Antimicrob Chemother; 2008 Jan; 61(1):206-9. PubMed ID: 17999972
[TBL] [Abstract][Full Text] [Related]
37. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials).
Durier C; Capitant C; Lascaux AS; Goujard C; Oksenhendler E; Poizot-Martin I; Viard JP; Weiss L; Netzer E; Delfraissy JF; Aboulker JP; Lévy Y
AIDS; 2007 Sep; 21(14):1887-97. PubMed ID: 17721096
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).
Molina JM; Levy Y; Fournier I; Hamonic S; Bentata M; Beck-Wirth G; Gougeon ML; Venet A; Madelaine I; Sereni D; Jeanblanc F; Boulet T; Simon F; Aboulker JP;
J Infect Dis; 2009 Jul; 200(2):206-15. PubMed ID: 19508157
[TBL] [Abstract][Full Text] [Related]
39. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
40. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
Smith PF; Ogundele A; Forrest A; Wilton J; Salzwedel K; Doto J; Allaway GP; Martin DE
Antimicrob Agents Chemother; 2007 Oct; 51(10):3574-81. PubMed ID: 17638699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
